At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 223 enrolled
Drug / intervention
ofatumumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With B-cell Chronic Lymphocytic Leukemia Who Have Failed Fludarabine and Alemtuzumab
In Brief
A Phase 2 clinical trial evaluating ofatumumab for Leukaemia, Lymphocytic, Chronic. Completed, enrolled 223 participants.
Detailed Summary
The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukaemia, Lymphocytic, Chronic
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJul 2006
Primary CompletionMay 2008
Study CompletionJun 2012
TodayJul 2026
First PostedJul 7, 2006
Enrollment StartJun 1, 2006
Primary CompletionMay 1, 2008
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.0 years ago
Interventions
ofatumumabdrug
Intravenous infusion